ID   PLCD4_HUMAN             Reviewed;         762 AA.
AC   Q9BRC7; Q53FS8;
DT   02-OCT-2007, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2001, sequence version 1.
DT   07-APR-2021, entry version 171.
DE   RecName: Full=1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-4 {ECO:0000305};
DE            Short=hPLCD4;
DE            EC=3.1.4.11 {ECO:0000269|PubMed:15140260};
DE   AltName: Full=Phosphoinositide phospholipase C-delta-4;
DE   AltName: Full=Phospholipase C-delta-4;
DE            Short=PLC-delta-4;
GN   Name=PLCD4 {ECO:0000312|HGNC:HGNC:9062};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, SUBCELLULAR LOCATION,
RP   TISSUE SPECIFICITY, AND CATALYTIC ACTIVITY.
RX   PubMed=15140260; DOI=10.1186/1476-4598-3-15;
RA   Leung D.W., Tompkins C., Brewer J., Ball A., Coon M., Morris V.,
RA   Waggoner D., Singer J.W.;
RT   "Phospholipase C delta-4 overexpression upregulates ErbB1/2 expression, Erk
RT   signaling pathway, and proliferation in MCF-7 cells.";
RL   Mol. Cancer 3:15-15(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Kidney proximal tubule;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   IDENTIFICATION.
RX   PubMed=10702683; DOI=10.1159/000015437;
RA   Kim H., Suh P.-G., Ryu S.H., Park S.H.;
RT   "Assignment of the human PLC delta4 gene (PLCD4) to human chromosome band
RT   2q35 by fluorescence in situ hybridization.";
RL   Cytogenet. Cell Genet. 87:254-255(1999).
RN   [5]
RP   TISSUE SPECIFICITY.
RX   PubMed=15505048; DOI=10.1167/iovs.04-0084;
RA   Landreville S., Coulombe S., Carrier P., Gelb M.H., Guerin S.L.,
RA   Salesse C.;
RT   "Expression of phospholipases A2 and C in human corneal epithelial cells.";
RL   Invest. Ophthalmol. Vis. Sci. 45:3997-4003(2004).
RN   [6]
RP   FUNCTION (ISOFORM 2), INTERACTION WITH GNAI3, GBA MOTIF, AND MUTAGENESIS OF
RP   224-LEU--LEU-228; PHE-227 AND 227-PHE-LEU-228.
RX   PubMed=30194280; DOI=10.1074/jbc.ra118.003580;
RA   Maziarz M., Broselid S., DiGiacomo V., Park J.C., Luebbers A.,
RA   Garcia-Navarrete L., Blanco-Canosa J.B., Baillie G.S., Garcia-Marcos M.;
RT   "A biochemical and genetic discovery pipeline identifies PLCdelta4b as a
RT   nonreceptor activator of heterotrimeric G-proteins.";
RL   J. Biol. Chem. 293:16964-16983(2018).
CC   -!- FUNCTION: Hydrolyzes the phosphatidylinositol 4,5-bisphosphate (PIP2)
CC       to generate 2 second messenger molecules diacylglycerol (DAG) and
CC       inositol 1,4,5-trisphosphate (IP3). DAG mediates the activation of
CC       protein kinase C (PKC), while IP3 releases Ca(2+) from intracellular
CC       stores. Required for acrosome reaction in sperm during fertilization,
CC       probably by acting as an important enzyme for intracellular Ca(2+)
CC       mobilization in the zona pellucida-induced acrosome reaction. May play
CC       a role in cell growth. Modulates the liver regeneration in cooperation
CC       with nuclear PKC. Overexpression up-regulates the Erk signaling pathway
CC       and proliferation. {ECO:0000269|PubMed:15140260}.
CC   -!- FUNCTION: [Isoform 2]: Acts as a non-receptor guanine nucleotide
CC       exchange factor which binds to and activates guanine nucleotide-binding
CC       protein (G-protein) alpha subunit GNAI3. {ECO:0000269|PubMed:30194280}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5-
CC         bisphosphate) + H2O = 1D-myo-inositol 1,4,5-trisphosphate + a 1,2-
CC         diacyl-sn-glycerol + H(+); Xref=Rhea:RHEA:33179, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:17815, ChEBI:CHEBI:58456,
CC         ChEBI:CHEBI:203600; EC=3.1.4.11;
CC         Evidence={ECO:0000269|PubMed:15140260};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:33180;
CC         Evidence={ECO:0000305|PubMed:15140260};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol) + H2O =
CC         1D-myo-inositol 1-phosphate + a 1,2-diacyl-sn-glycerol + H(+);
CC         Xref=Rhea:RHEA:43484, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:17815, ChEBI:CHEBI:57880, ChEBI:CHEBI:58433;
CC         Evidence={ECO:0000269|PubMed:15140260};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43485;
CC         Evidence={ECO:0000305|PubMed:15140260};
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU00041};
CC       Note=Binds 3 Ca(2+) ions per subunit. Two of the Ca(2+) ions are bound
CC       to the C2 domain. {ECO:0000250};
CC   -!- SUBUNIT: Interacts with GRIP1 (By similarity).
CC       {ECO:0000250|UniProtKB:Q8K3R3}.
CC   -!- SUBUNIT: [Isoform 2]: Interacts (via GBA motif) with guanine
CC       nucleotide-binding protein G(i) alpha subunit GNAI3 (inactive GDP-bound
CC       form); high-affinity interaction (PubMed:30194280).
CC       {ECO:0000269|PubMed:30194280}.
CC   -!- SUBUNIT: [Isoform 1]: Interacts (via GBA motif) with guanine
CC       nucleotide-binding protein G(i) alpha subunit GNAI3 (inactive GDP-bound
CC       form); low-affinity interaction (PubMed:30194280).
CC       {ECO:0000269|PubMed:30194280}.
CC   -!- INTERACTION:
CC       Q9BRC7; P50221: MEOX1; NbExp=3; IntAct=EBI-748799, EBI-2864512;
CC       Q9BRC7; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-748799, EBI-16439278;
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000250}; Peripheral membrane
CC       protein {ECO:0000250}. Nucleus {ECO:0000250}. Cytoplasm
CC       {ECO:0000269|PubMed:15140260}. Endoplasmic reticulum {ECO:0000250}.
CC       Note=Localizes primarily to intracellular membranes mostly to the
CC       endoplasmic reticulum.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9BRC7-1; Sequence=Displayed;
CC       Name=2; Synonyms=PLCD4b;
CC         IsoId=Q9BRC7-2; Sequence=VSP_028501, VSP_028502;
CC   -!- TISSUE SPECIFICITY: Highly expressed in skeletal muscle and kidney
CC       tissues, and at moderate level in intestinal tissue. Expressed in
CC       corneal epithelial cells. {ECO:0000269|PubMed:15140260,
CC       ECO:0000269|PubMed:15505048}.
CC   -!- DOMAIN: The PDZ-binding motif mediates the interaction with GRIP1.
CC   -!- DOMAIN: The C2 domain mediates pre-localization to the membrane prior
CC       to Ca(2+) import and non-selective Ca(2+)-mediated targeting to various
CC       cellular membranes.
CC   -!- DOMAIN: The PH domain is not a critical determinant of the membrane
CC       localization.
CC   -!- DOMAIN: The GBA (G-alpha binding and activating) motif mediates binding
CC       to the alpha subunits of guanine nucleotide-binding proteins (G
CC       proteins). {ECO:0000269|PubMed:30194280}.
CC   -!- MISCELLANEOUS: [Isoform 1]: Acceptor splice site between exons 4 and 5
CC       is non-canonical but conserved through species for that particular
CC       gene.
CC   -!- MISCELLANEOUS: [Isoform 2]: May be produced at very low levels due to a
CC       premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC       decay. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY512961; AAS82574.1; -; mRNA.
DR   EMBL; AK223203; BAD96923.1; -; mRNA.
DR   EMBL; BC006355; AAH06355.1; -; mRNA.
DR   CCDS; CCDS46516.1; -. [Q9BRC7-1]
DR   RefSeq; NP_116115.1; NM_032726.3. [Q9BRC7-1]
DR   SMR; Q9BRC7; -.
DR   BioGRID; 124273; 32.
DR   IntAct; Q9BRC7; 4.
DR   STRING; 9606.ENSP00000388631; -.
DR   SwissLipids; SLP:000001758; -.
DR   iPTMnet; Q9BRC7; -.
DR   PhosphoSitePlus; Q9BRC7; -.
DR   BioMuta; PLCD4; -.
DR   DMDM; 74732863; -.
DR   jPOST; Q9BRC7; -.
DR   MassIVE; Q9BRC7; -.
DR   PaxDb; Q9BRC7; -.
DR   PeptideAtlas; Q9BRC7; -.
DR   PRIDE; Q9BRC7; -.
DR   ProteomicsDB; 78756; -. [Q9BRC7-1]
DR   ProteomicsDB; 78757; -. [Q9BRC7-2]
DR   Antibodypedia; 4087; 106 antibodies.
DR   DNASU; 84812; -.
DR   Ensembl; ENST00000417849; ENSP00000396942; ENSG00000115556. [Q9BRC7-1]
DR   Ensembl; ENST00000450993; ENSP00000388631; ENSG00000115556. [Q9BRC7-1]
DR   GeneID; 84812; -.
DR   KEGG; hsa:84812; -.
DR   UCSC; uc061smf.1; human. [Q9BRC7-1]
DR   CTD; 84812; -.
DR   DisGeNET; 84812; -.
DR   GeneCards; PLCD4; -.
DR   HGNC; HGNC:9062; PLCD4.
DR   HPA; ENSG00000115556; Group enriched (retina, skeletal muscle, smooth muscle).
DR   MIM; 605939; gene.
DR   neXtProt; NX_Q9BRC7; -.
DR   OpenTargets; ENSG00000115556; -.
DR   PharmGKB; PA33390; -.
DR   VEuPathDB; HostDB:ENSG00000115556.13; -.
DR   eggNOG; KOG0169; Eukaryota.
DR   GeneTree; ENSGT00940000156180; -.
DR   HOGENOM; CLU_002738_0_2_1; -.
DR   InParanoid; Q9BRC7; -.
DR   OrthoDB; 368239at2759; -.
DR   PhylomeDB; Q9BRC7; -.
DR   TreeFam; TF313216; -.
DR   PathwayCommons; Q9BRC7; -.
DR   Reactome; R-HSA-1855204; Synthesis of IP3 and IP4 in the cytosol.
DR   SIGNOR; Q9BRC7; -.
DR   BioGRID-ORCS; 84812; 2 hits in 988 CRISPR screens.
DR   ChiTaRS; PLCD4; human.
DR   GeneWiki; PLCD4; -.
DR   GenomeRNAi; 84812; -.
DR   Pharos; Q9BRC7; Tbio.
DR   PRO; PR:Q9BRC7; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q9BRC7; protein.
DR   Bgee; ENSG00000115556; Expressed in skeletal muscle tissue and 152 other tissues.
DR   ExpressionAtlas; Q9BRC7; baseline and differential.
DR   Genevisible; Q9BRC7; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0001965; F:G-protein alpha-subunit binding; IPI:UniProtKB.
DR   GO; GO:0005085; F:guanyl-nucleotide exchange factor activity; IDA:UniProtKB.
DR   GO; GO:0004435; F:phosphatidylinositol phospholipase C activity; IBA:GO_Central.
DR   GO; GO:0007340; P:acrosome reaction; IEA:InterPro.
DR   GO; GO:0043647; P:inositol phosphate metabolic process; TAS:Reactome.
DR   GO; GO:0016042; P:lipid catabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0046488; P:phosphatidylinositol metabolic process; IEA:InterPro.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; IBA:GO_Central.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; IDA:UniProtKB.
DR   Gene3D; 2.30.29.30; -; 1.
DR   Gene3D; 2.60.40.150; -; 1.
DR   Gene3D; 3.20.20.190; -; 2.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR035892; C2_domain_sf.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR018247; EF_Hand_1_Ca_BS.
DR   InterPro; IPR002048; EF_hand_dom.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR001192; PI-PLC_fam.
DR   InterPro; IPR028387; PLC-delta4.
DR   InterPro; IPR017946; PLC-like_Pdiesterase_TIM-brl.
DR   InterPro; IPR015359; PLC_EF-hand-like.
DR   InterPro; IPR000909; PLipase_C_PInositol-sp_X_dom.
DR   InterPro; IPR001711; PLipase_C_Pinositol-sp_Y.
DR   PANTHER; PTHR10336; PTHR10336; 1.
DR   PANTHER; PTHR10336:SF31; PTHR10336:SF31; 1.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF13202; EF-hand_5; 1.
DR   Pfam; PF09279; EF-hand_like; 1.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF00388; PI-PLC-X; 1.
DR   Pfam; PF00387; PI-PLC-Y; 1.
DR   PRINTS; PR00390; PHPHLIPASEC.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00054; EFh; 3.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00148; PLCXc; 1.
DR   SMART; SM00149; PLCYc; 1.
DR   SUPFAM; SSF47473; SSF47473; 1.
DR   SUPFAM; SSF51695; SSF51695; 1.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS00018; EF_HAND_1; 2.
DR   PROSITE; PS50222; EF_HAND_2; 3.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS50007; PIPLC_X_DOMAIN; 1.
DR   PROSITE; PS50008; PIPLC_Y_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Calcium; Cytoplasm; Endoplasmic reticulum;
KW   Guanine-nucleotide releasing factor; Hydrolase; Lipid degradation;
KW   Lipid metabolism; Membrane; Metal-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; Transducer.
FT   CHAIN           1..762
FT                   /note="1-phosphatidylinositol 4,5-bisphosphate
FT                   phosphodiesterase delta-4"
FT                   /id="PRO_0000306824"
FT   DOMAIN          16..124
FT                   /note="PH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          134..169
FT                   /note="EF-hand 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   DOMAIN          170..205
FT                   /note="EF-hand 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   DOMAIN          203..237
FT                   /note="EF-hand 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   DOMAIN          290..435
FT                   /note="PI-PLC X-box"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00270"
FT   DOMAIN          493..609
FT                   /note="PI-PLC Y-box"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00271"
FT   DOMAIN          609..736
FT                   /note="C2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   CA_BIND         147..158
FT                   /note="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   CA_BIND         183..194
FT                   /note="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   REGION          26..53
FT                   /note="Substrate binding"
FT                   /evidence="ECO:0000250"
FT   MOTIF           213..243
FT                   /note="GBA"
FT                   /evidence="ECO:0000269|PubMed:30194280"
FT   MOTIF           731..734
FT                   /note="PDZ-binding"
FT   COMPBIAS        440..473
FT                   /note="Glu-rich"
FT   COMPBIAS        479..486
FT                   /note="Poly-Lys"
FT   ACT_SITE        305
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00270"
FT   ACT_SITE        350
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00270"
FT   METAL           306
FT                   /note="Calcium 1; catalytic"
FT                   /evidence="ECO:0000250"
FT   METAL           335
FT                   /note="Calcium 1; catalytic"
FT                   /evidence="ECO:0000250"
FT   METAL           337
FT                   /note="Calcium 1; catalytic"
FT                   /evidence="ECO:0000250"
FT   METAL           384
FT                   /note="Calcium 1; catalytic"
FT                   /evidence="ECO:0000250"
FT   METAL           650
FT                   /note="Calcium 2; via carbonyl oxygen"
FT                   /evidence="ECO:0000250"
FT   METAL           652
FT                   /note="Calcium 2"
FT                   /evidence="ECO:0000250"
FT   METAL           676
FT                   /note="Calcium 2"
FT                   /evidence="ECO:0000250"
FT   METAL           705
FT                   /note="Calcium 3"
FT                   /evidence="ECO:0000250"
FT   METAL           706
FT                   /note="Calcium 3; via carbonyl oxygen"
FT                   /evidence="ECO:0000250"
FT   METAL           707
FT                   /note="Calcium 3"
FT                   /evidence="ECO:0000250"
FT   BINDING         433
FT                   /note="Substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         435
FT                   /note="Substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         522
FT                   /note="Substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         549
FT                   /note="Substrate"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         457
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62711"
FT   VAR_SEQ         259..272
FT                   /note="KLRHVLSMDGFLSY -> ASEEDPGEGEEVNT (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15140260"
FT                   /id="VSP_028501"
FT   VAR_SEQ         273..762
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15140260"
FT                   /id="VSP_028502"
FT   MUTAGEN         224..228
FT                   /note="LLEFL->ALEAA: Abolishes binding to and activation of
FT                   GNAI3."
FT                   /evidence="ECO:0000269|PubMed:30194280"
FT   MUTAGEN         227..228
FT                   /note="FL->AA: Abolishes binding to GNAI3."
FT                   /evidence="ECO:0000269|PubMed:30194280"
FT   MUTAGEN         227
FT                   /note="F->A: Marked but incomplete decrease in GNAI3
FT                   binding and reduced activation of G-protein signaling."
FT                   /evidence="ECO:0000269|PubMed:30194280"
FT   CONFLICT        98
FT                   /note="R -> H (in Ref. 2; BAD96923)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   762 AA;  87585 MW;  5444BE5CE2AEA3EF CRC64;
     MASLLQDQLT TDQDLLLMQE GMPMRKVRSK SWKKLRYFRL QNDGMTVWHA RQARGSAKPS
     FSISDVETIR NGHDSELLRS LAEELPLEQG FTIVFHGRRS NLDLMANSVE EAQIWMRGLQ
     LLVDLVTSMD HQERLDQWLS DWFQRGDKNQ DGKMSFQEVQ RLLHLMNVEM DQEYAFSLFQ
     AADTSQSGTL EGEEFVQFYK ALTKRAEVQE LFESFSADGQ KLTLLEFLDF LQEEQKERDC
     TSELALELID RYEPSDSGKL RHVLSMDGFL SYLCSKDGDI FNPACLPIYQ DMTQPLNHYF
     ICSSHNTYLV GDQLCGQSSV EGYIRALKRG CRCVEVDVWD GPSGEPVVYH GHTLTSRILF
     KDVVATVAQY AFQTSDYPVI LSLETHCSWE QQQTMARHLT EILGEQLLST TLDGVLPTQL
     PSPEELRRKI LVKGKKLTLE EDLEYEEEEA EPELEESELA LESQFETEPE PQEQNLQNKD
     KKKKSKPILC PALSSLVIYL KSVSFRSFTH SKEHYHFYEI SSFSETKAKR LIKEAGNEFV
     QHNTWQLSRV YPSGLRTDSS NYNPQELWNA GCQMVAMNMQ TAGLEMDICD GHFRQNGGCG
     YVLKPDFLRD IQSSFHPEKP ISPFKAQTLL IQVISGQQLP KVDKTKEGSI VDPLVKVQIF
     GVRLDTARQE TNYVENNGFN PYWGQTLCFR VLVPELAMLR FVVMDYDWKS RNDFIGQYTL
     PWTCMQQGYR HIHLLSKDGI SLRPASIFVY ICIQEGLEGD ES
//
